The FDA has cleared UBC's Cimzia for the treatment of moderate to severe Crohn's disease in adults who have failed to respond to conventional therapies. UBC, however, must conduct postmarketing studies to assess the injectable drug's long-term safety because it affects the immune system and inhibits tumor necrosis factor, rendering patients more susceptible to life-threatening infections as well as lymphoma and other cancers, the agency said.

Related Summaries